is tirzepatide a hormone FDA approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 receptors - Eli Lilly Tirzepatide Injections for Medical Weight
Description
From weight loss breakthroughsto type 2 diabetes management, and even anti-aging medicine, these treatments offer extraordinary promise.But with innovation comes risk

Lilly plans regulatory submissions in 2025 for obesity and in 2026 for type 2 diabetes

Discover why this combination isn't routinely recommended in the UK, the potential risks involved, what healthcare professionals advise, and evidence-based alternatives for safe, effective weight management.

Compared with DPP-4 inhibitors, the lower rate of hyperkalemia was consistently observed across individual agents in the SGLT-2 inhibitor (canagliflozin, dapagliflozin, empagliflozin) and GLP-1 receptor agonist (dulaglutide, exenatide, liraglutide, semaglutide) classes
